Shares of Boston Scientific rose 3.03% to $36.34 at 15:58 EST on Tuesday, following last session’s downward trend. NYSE Composite is rising 1.16% to $14,543.03, following last session’s downward trend, This seems, as yet, an all-around positive trend trading session today.

Boston Scientific’s last close was $35.27, 26.94% below its 52-week high of $46.13.

Boston Scientific’s Sales

Boston Scientific’s sales growth is a negative 1.1% for the present quarter and 8.2% for the next. The company’s growth estimates for the present quarter is a negative 30.4% and positive 28.6% for the next.

Boston Scientific’s Revenue

Year-on-year quarterly revenue growth declined by 1.8%, now sitting on 10.11B for the twelve trailing months.

Volatility

Boston Scientific’s last day, last week, and last month’s average volatility was a negative 1.93%, a positive 0.39%, and a positive 0.16%, respectively.

Boston Scientific’s last day, last week, and last month’s high and low average amplitude percentage was 3.05%, 1.75%, and 1.95%, respectively.

Boston Scientific’s Stock Yearly Top and Bottom Value

Boston Scientific’s stock is valued at $36.34 at 15:58 EST, way below its 52-week high of $46.13 and way above its 52-week low of $24.10.

Boston Scientific’s Moving Average

Boston Scientific’s worth is above its 50-day moving average of $34.49 and under its 200-day moving average of $37.14.

Previous days news about Boston Scientific

Shareholder alert; pomerantz law firm reminds shareholders with losses on their investment in Boston Scientific corporation of class action lawsuit and upcoming deadline – BSX. According to Business Insider on Sunday, 3 January, "If you are a shareholder who purchased Boston Scientific securities during the Class Period, you have until February 2, 2021, to ask the Court to appoint you as Lead Plaintiff for the class.", "Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers."

LEAVE A REPLY

Please enter your comment!
Please enter your name here